ASNB - AdvanSource Biomaterials Corporation

Other OTC - Other OTC Delayed Price. Currency in USD

AdvanSource Biomaterials Corporation

229 Andover Street
Wilmington, MA 01887
United States

Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael F. AdamsPres, CEO & Director336kN/A1956
Ms. Khristine L. CarrollExec. VP of Commercial Operations226kN/A1973
Mr. Ajay NagleHead of LegalN/AN/AN/A
Mr. Thomas J. CarcelDirector of Worldwide Sales & Marketing for Gish Biomedical IncN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


AdvanSource Biomaterials Corporation develops polymer materials for use in the design and development of medical devices used for treating a range of anatomical sites and disease states. It offers polymers under the ChronoFilm, ChronoFlex, ChronoThane, ChronoPrene, ChronoSil, HydroThane, HydroMed, and PolyBlend trade names. The company also manufactures specialty hydrophilic polyurethanes. It sells its products directly to the customers in the United States. The company was formerly known as CardioTech International, Inc. and changed its name to AdvanSource Biomaterials Corporation in October 2008. AdvanSource Biomaterials Corporation was founded in 1993 and is headquartered in Wilmington, Massachusetts.

Corporate Governance

AdvanSource Biomaterials Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.